Gleason 5级前列腺癌:外照射联合近距离放疗与根治性前列腺切除术的生存比较
基于SEER数据库2004-2013年7669例Gleason 5级前列腺癌患者,比较外照射联合近距离放疗(EBRT+BT)与根治性前列腺切除术(RP)后的前列腺癌特异性死亡率(PCSM)。倾向性评分匹配后,两组PCSM无差异(调整HR 1.018,P=.910),5年累积PCSM分别为5.6%和6.1%。
要点
- 倾向性评分匹配后,RP与EBRT+BT的PCSM无显著差异(调整HR 1.018,P=.910)。
- 5年累积PCSM:RP组5.6%,EBRT+BT组6.1%。
- 原发Gleason 5级患者PCSM显著高于继发Gleason 5级,无论治疗方式。
核心结论
- 在倾向性评分匹配平衡患者特征后,RP与EBRT+BT在Gleason 5级前列腺癌患者中提供等效的PCSM。
研究设计与样本
- 基于SEER数据库的回顾性队列研究,纳入2004-2013年7669例经穿刺活检或经尿道前列腺电切诊断的Gleason 5级前列腺癌患者,接受EBRT+BT或RP。
- 采用倾向性评分匹配平衡患者特征,使用多因素Fine and Gray竞争风险模型比较PCSM,并调整年龄、种族、Gleason评分和临床T分期。
主要发现
- RP组患者较EBRT+BT组更年轻、Gleason 5级负荷更低、T分期更低且其他原因死亡率更低。
- 倾向性评分匹配后,RP与EBRT+BT组PCSM无差异(调整HR 1.018;P=.910)。
- RP组和EBRT+BT组的5年累积PCSM发生率分别为5.6%和6.1%。
- 无论治疗方式如何,原发Gleason 5级患者的PCSM显著高于继发Gleason 5级患者。
关键数值与推荐
- 倾向性评分匹配后PCSM比较的调整HR为1.018(P=.910)。
- RP组5年累积PCSM发生率为5.6%,EBRT+BT组为6.1%。
临床怎么用
- 对于经穿刺活检或经尿道前列腺电切诊断的Gleason 5级前列腺癌患者,RP和EBRT+BT可作为等效的PCSM治疗选择。
- 原发Gleason 5级患者PCSM风险更高,无论选择何种治疗方式均需加强关注。
局限性
- 本研究为基于SEER数据库的回顾性队列研究,可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with prostate cancer (PCa) containing Gleason pattern (GP) 5 disease experience a greater and earlier incidence of prostate cancer-specific mortality (PCSM) than general PCa patients. This affords the statistical power to compare PCSM outcomes among different treatment modalities even when restricting the analysis to patients treated in the modern era. The purpose of the present study was to compare the survival outcomes among patients with GP 5 PCa on needle core biopsy or transurethral resection of the prostate who underwent extremely dose-escalated radiation therapy (RT; exemplified by external beam RT with a brachytherapy boost [EBRT + BT]) versus radical prostatectomy (RP) in the modern era. METHODS AND MATERIALS: A total of 7669 men with a diagnosis of GP 5 PCa from 2004 to 2013 who had undergone EBRT + BT or RP were identified using the Surveillance, Epidemiology, and End Results database. After propensity score matching to balance the patient characteristics, PCSM was compared between modalities using a multivariate Fine and Gray competing risk model that accounted for other-cause mortality, with adjustment for age, race, GP, and clinical T stage. RESULTS: Patients treated with RP were younger and had a lower burden of GP 5, lower T stage, and lower other-cause mortality than patients who underwent EBRT + BT. After propensity score matching, no difference was found in PCSM between the RP and EBRT + BT groups (adjusted hazard ratio 1.018; P=.910). The cumulative 5-year PCSM incidence rates were 5.6% and 6.1% for patients undergoing RP and EBRT + BT, respectively. Patients with primary GP 5 experienced significantly greater PCSM than those with secondary GP 5, regardless of the treatment modality. CONCLUSIONS: For patients with GP 5 PCa found on needle core biopsy or transurethral resection of the prostate, RP and EBRT + BT offer equivalent PCSM in a competing risk model after propensity score matching to balance the differences in patient characteristics.
引用
- Wang C, Kishan AU, Kamrava M, et al. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. Int J Radiat Oncol Biol Phys. 2017. PMID: 28721887. doi:10.1016/j.ijrobp.2017.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。